ARTICLE | Company News
aRigen, Green Cross deal
January 31, 2011 8:00 AM UTC
aRigen granted Green Cross exclusive rights in Korea to develop and commercialize WAP-8294A2. Green Cross will begin a Korean Phase II trial of the injectable depsipeptide antibiotic to treat infect...